Pfizer ROE 2010-2024 | PFE
Current and historical return on equity (ROE) values for Pfizer (PFE) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Pfizer ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-09-30 |
$4.25B |
|
6.30% |
| 2024-06-30 |
$-2.60B |
$87.98B |
-2.83% |
| 2024-03-31 |
$-0.31B |
$92.56B |
-0.33% |
| 2023-12-31 |
$2.12B |
$89.29B |
2.19% |
| 2023-09-30 |
$10.48B |
$97.20B |
10.65% |
| 2023-06-30 |
$21.47B |
$99.29B |
22.06% |
| 2023-03-31 |
$29.05B |
$101.24B |
30.78% |
| 2022-12-31 |
$31.37B |
$95.92B |
34.96% |
| 2022-09-30 |
$29.77B |
$92.89B |
34.97% |
| 2022-06-30 |
$29.31B |
$87.47B |
36.23% |
| 2022-03-31 |
$24.97B |
$82.69B |
32.59% |
| 2021-12-31 |
$21.98B |
$77.46B |
30.05% |
| 2021-09-30 |
$19.43B |
$75.97B |
27.90% |
| 2021-06-30 |
$12.76B |
$70.32B |
19.03% |
| 2021-03-31 |
$10.68B |
$68.87B |
16.28% |
| 2020-12-31 |
$9.16B |
$63.47B |
14.15% |
| 2020-09-30 |
$7.73B |
$65.50B |
11.94% |
| 2020-06-30 |
$13.94B |
$64.56B |
21.55% |
| 2020-03-31 |
$15.50B |
$65.34B |
24.39% |
| 2019-12-31 |
$16.03B |
$63.45B |
25.86% |
| 2019-09-30 |
$16.22B |
$65.40B |
26.13% |
| 2019-06-30 |
$12.65B |
$59.92B |
19.88% |
| 2019-03-31 |
$11.48B |
$59.16B |
17.34% |
| 2018-12-31 |
$11.15B |
$63.76B |
16.16% |
| 2018-09-30 |
$23.82B |
$71.66B |
33.55% |
| 2018-06-30 |
$22.55B |
$70.12B |
32.98% |
| 2018-03-31 |
$21.75B |
$70.54B |
33.20% |
| 2017-12-31 |
$21.31B |
$71.66B |
34.06% |
| 2017-09-30 |
$9.81B |
$61.11B |
16.46% |
| 2017-06-30 |
$8.32B |
$58.69B |
13.82% |
| 2017-03-31 |
$7.30B |
$58.75B |
11.90% |
| 2016-12-31 |
$7.22B |
$59.84B |
11.55% |
| 2016-09-30 |
$6.27B |
$63.60B |
9.83% |
| 2016-06-30 |
$7.04B |
$63.07B |
10.90% |
| 2016-03-31 |
$7.62B |
$63.35B |
11.61% |
| 2015-12-31 |
$6.96B |
$65.00B |
10.43% |
| 2015-09-30 |
$8.36B |
$67.12B |
12.23% |
| 2015-06-30 |
$8.90B |
$67.18B |
12.50% |
| 2015-03-31 |
$9.18B |
$67.59B |
12.47% |
| 2014-12-31 |
$9.14B |
$71.62B |
11.98% |
| 2014-09-30 |
$10.48B |
$78.31B |
13.52% |
| 2014-06-30 |
$10.40B |
$76.96B |
13.42% |
| 2014-03-31 |
$21.58B |
$78.07B |
27.67% |
| 2013-12-31 |
$22.00B |
$76.62B |
27.78% |
| 2013-09-30 |
$25.75B |
$78.35B |
32.00% |
| 2013-06-30 |
$26.37B |
$78.98B |
32.39% |
| 2013-03-31 |
$15.53B |
$82.83B |
19.02% |
| 2012-12-31 |
$14.57B |
$81.68B |
17.80% |
| 2012-09-30 |
$9.69B |
$82.12B |
11.81% |
| 2012-06-30 |
$10.22B |
$79.96B |
12.14% |
| 2012-03-31 |
$9.58B |
$83.68B |
11.08% |
| 2011-12-31 |
$10.01B |
$82.62B |
11.35% |
| 2011-09-30 |
$11.46B |
$90.53B |
12.79% |
| 2011-06-30 |
$8.59B |
$88.96B |
9.65% |
| 2011-03-31 |
$8.45B |
$90.53B |
9.56% |
| 2010-12-31 |
$8.26B |
$88.27B |
9.35% |
| 2010-09-30 |
$6.13B |
$88.07B |
6.90% |
| 2010-06-30 |
$8.15B |
$86.88B |
9.77% |
| 2010-03-31 |
$7.93B |
$90.08B |
10.23% |
| 2009-12-31 |
$8.64B |
$90.45B |
12.32% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$159.177B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
